Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review

References

• Control ECfDPa. Rapid risk assessment: cluster of pneumonia cases caused by a novel coronavirus, Wuhan, China, 2020 2020 [updated 2020 11 Feb; cited 2020 Aug 18]. Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-cluster-pneumonia-cases-caused-novel-coronavirus-wuhan
   Google Scholar
• WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020 2020 [updated 11 Feb 2020; cited 2020; cited 2020 Feb 2020; cited 2020 Aug 11 Feb 2020; cited 2020 Aug 18. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
   Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):1025–1031.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69–75.
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012–10017.
   PubMed Web of Science ®Google Scholar
• Chan JF, Yao Y, Yeung ML, et al. Treatment with Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015;212(12):1904–1913.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020;25(4):668–688.
   PubMed Web of Science ®Google Scholar
• Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399–406.
   PubMedGoogle Scholar
• Park SY, Lee JS, Kim J, et al. 2491. Post-exposure prophylaxis with ribavirin plus lopinavir/ritonavir for Middle East respiratory syndrome in healthcare workers. Open Forum Infect Dis. 2018;5(suppl_1):S747–S748.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed). 2009;339(jul21 1):b2700.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Medicine (Baltimore). 2020doi: 10.1016/j.medj.2020.04.001 [Epub ahead of print].
   Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study. Engineering. 2020 Mar 18.doi: 10.1016/j.eng.2020.03.007 [Epub ahead of print].
   Web of Science ®Google Scholar
• Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020;12(4):322–325.
   PubMed Web of Science ®Google Scholar
• Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390–3396.
   PubMed Web of Science ®Google Scholar
• Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31–35.
   PubMed Web of Science ®Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020;81(1):e1–e5.
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim EJ, Kwon HH, et al. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J Intern Med. 2020 Jun 16.doi: 10.3904/kjim.2020.224.Online ahead of print.
   Web of Science ®Google Scholar
• Lan X, Shao C, Zeng X, et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study. MedRxiv. 2020 Apr 25;20079079.
   Google Scholar
• Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020;95:183–191.
   PubMed Web of Science ®Google Scholar
• Panagopoulos P, Petrakis V, Panopoulou M, et al. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. J Chemother. 2020;1-5. doi:10.1080/1120009X.2020.1775424.
   Google Scholar
• Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 2020;56(1):2000799.
   Web of Science ®Google Scholar
• Yu C, Zhang Z, Guo Y, et al. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study. J Med Virol. 2020. doi: 10.1002/jmv.26260.
   Web of Science ®Google Scholar
• Zhang Z, Wang S, Tu X, et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol. 2020. doi: 10.1002/jmv.26141.Online ahead of print.
   Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–e23.
   PubMed Web of Science ®Google Scholar
• WHO. R&D Blueprint and COVID-19 2020 [cited 2020 Oct 12]. Available from: https://www.who.int/teams/blueprint/covid-19
   Google Scholar
• Commission CMH. Chinese management guideline for COVID-19 (version 6.0): Chinese municipal health commission; 2020 cited 2020 Feb 19, [in Chinese].
   Google Scholar
• Health NDoP. No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY 2020 [cited 2020 Aug 19]. Available from: https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery
   Google Scholar
• WHO. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 2020 [cited 2020 Oct 12]. Available from: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
   Google Scholar
• Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4(5):1023–1033.
   PubMedGoogle Scholar
• Barretto N, Jukneliene D, Ratia K, et al. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol. 2005;79(24):15189–15198.
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Hilgenfeld R, Zabel P. Molecular mechanisms of severe acute respiratory syndrome (SARS). Respir Res. 2005;6(1):8.
   PubMedGoogle Scholar
• Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–331.
   PubMed Web of Science ®Google Scholar
• Nitulescu GM, Paunescu H, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med. 2020;46(2):467–488.
   PubMed Web of Science ®Google Scholar
• Baldelli S, Corbellino M, Clementi E, et al. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother. 2020;75(9):2704–2706.
   Web of Science ®Google Scholar
• Solas C, Poizot-Martin I, Drogoul MP, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol. 2004;57(4):436–440.
   PubMed Web of Science ®Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa478. Online ahead of print.
   Google Scholar
• NIH. Lopinavir/Ritonavir and Other HIV Protease Inhibitors 2020 [updated 2020 Jul 17; cited 2020 Oct 12]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/lopinavir-ritonavir-and-other-hiv-protease-inhibitors/
   Google Scholar